Source:http://linkedlifedata.com/resource/pubmed/id/19372982
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2009-4-17
|
| pubmed:abstractText |
Pharmacokinetic and drug-drug interaction studies are conducted in both healthy volunteers and the target population (HIV-infected patients), but there is little discussion of the potential for differences in drug disposition between the two groups. It is important to recognize that the pharmacokinetics of drugs may be altered in HIV-infected persons as compared with healthy individuals. The aim of this review is to highlight some of the important differences in drug handling between healthy volunteers and HIV-infected individuals, focusing on protease inhibitors.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:status |
PubMed-not-MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
1746-6318
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
3
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
296-305
|
| pubmed:year |
2008
|
| pubmed:articleTitle |
Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons.
|
| pubmed:affiliation |
Department of Pharmacology & Therapeutics, University of Liverpool, Liverpool L69 3GF, UK. laurad@liv.ac.uk
|
| pubmed:publicationType |
Journal Article
|